Bio-Path Holdings, Inc. (BPTH): Price and Financial Metrics


Bio-Path Holdings, Inc. (BPTH): $3.90

0.03 (+0.78%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add BPTH to Watchlist
Sign Up

Industry: Biotech


Ranked

of

in industry

BPTH Stock Price Chart Interactive Chart >

Price chart for BPTH

BPTH Price/Volume Stats

Current price $3.90 52-week high $8.62
Prev. close $3.87 52-week low $2.68
Day low $3.89 Volume 478
Day high $3.90 Avg. volume 54,701
50-day MA $3.35 Dividend yield N/A
200-day MA $3.97 Market Cap 27.92M

Bio-Path Holdings, Inc. (BPTH) Company Bio


Bio-Path Holdings, Inc. focuses on developing therapeutic products utilizing its proprietary liposomal delivery technology to systemically distribute nucleic acid drugs throughout the human body with a simple intravenous transfusion. The company was founded in 2007 and is based in Bellaire, Texas.


BPTH Latest News Stream


Event/Time News Detail
Loading, please wait...

BPTH Latest Social Stream


Loading social stream, please wait...

View Full BPTH Social Stream

Latest BPTH News From Around the Web

Below are the latest news stories about Bio-Path Holdings Inc that investors may wish to consider to help them evaluate BPTH as an investment opportunity.

Bio-Path Holdings to Present at H.C. Wainwright BioConnect 2022 Virtual Conference

HOUSTON, Jan. 05, 2022 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (NASDAQ: BPTH), a biotechnology company leveraging its proprietary DNAbilize® antisense RNAi nanoparticle technology to develop a portfolio of targeted nucleic acid cancer drugs, today announced that Peter Nielsen, Chief Executive Officer, will participate in a pre-recorded presentation at the H.C. Wainwright BioConnect 2022 Virtual Conference made available on Monday, January 10, 2022 at 7:00 a.m. ET. An audio webcast of the pr

Yahoo | January 5, 2022

Bio-Path Holdings Presents Data from Ongoing Phase 2 Study of Prexigebersen at 2021 American Society of Hematology Annual Meeting

Preliminary Prexigebersen Data Show Signs of Safety and Efficacy in High Risk AML PatientsHOUSTON, Dec. 13, 2021 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (NASDAQ: BPTH), a biotechnology company leveraging its proprietary DNAbilize® antisense RNAi nanoparticle technology to develop a portfolio of targeted nucleic acid cancer drugs, today announces a poster highlighting the safety and preliminary efficacy data of its Phase 2 study of prexigebersen (BP1001) was presented at the 2021 American So

Yahoo | December 13, 2021

Here's Why We're Not Too Worried About Bio-Path Holdings' (NASDAQ:BPTH) Cash Burn Situation

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...

Yahoo | December 6, 2021

Brokerages Anticipate Bio-Path Holdings, Inc. (NASDAQ:BPTH) to Announce -$0.32 EPS

Analysts expect Bio-Path Holdings, Inc. (NASDAQ:BPTH) to post earnings of ($0.32) per share for the current fiscal quarter, according to Zacks Investment Research. Zero analysts have provided estimates for Bio-Paths earnings. The highest EPS estimate is ($0.29) and the lowest is ($0.35). Bio-Path posted earnings of ($0.57) per share during the same quarter last year, []

Transcript Daily | November 22, 2021

Bio-Path Holdings, Inc. (BPTH) CEO Peter Nielsen on Q3 2021 Results - Earnings Call Transcript

No summary available.

Seeking Alpha | November 12, 2021

Read More 'BPTH' Stories Here

BPTH Price Returns

1-mo 15.04%
3-mo 1.04%
6-mo 3.45%
1-year -40.46%
3-year -73.32%
5-year -95.00%
YTD 3.45%
2021 7.71%
2020 -56.20%
2019 128.29%
2018 -91.25%
2017 -85.19%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.4071 seconds.